Rainbow Children's Medicare (RAINBOW) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
12 Apr, 2026Executive summary
Achieved 12% year-over-year revenue growth in Q3 FY26, reaching ₹4,454 million, with PAT up 7% to ₹739 million and EBITDA up 9% to ₹1,470 million.
Operational expansion included new hospitals in Warangal, Guwahati, and Rajahmundry, increasing total bed capacity to 2,375 across 23 hospitals in 9 cities.
Leadership strengthened with the appointment of Mr. Abrar Ali Dalal as CEO and other senior hires to drive growth and operational efficiency.
Unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025 were reviewed and approved by the Board on 28 January 2026.
Statutory auditors issued unmodified (clean) limited review reports for both standalone and consolidated results.
Financial highlights
Q3 FY26 consolidated revenue was ₹4,454.48 million, up 12% year-over-year; PAT at ₹738.97 million, up 7%; EBITDA at ₹1,470 million, up 9%.
Nine-month FY26 consolidated revenue was ₹12,431.76 million, up 9% year-over-year; PAT at ₹2,033.26 million, up 8%; EBITDA at ₹3,995 million, up 6%.
Q3 EBITDA margin at 33%; nine-month EBITDA margin at 32.1%.
ARPOB for Q3 FY26 was ₹58,362 (+9% YoY); 9M FY26: ₹59,324 (+12% YoY).
Cash position of INR 579 crore as of Dec 31, 2025, supporting ongoing capex and M&A plans.
Outlook and guidance
Targeting occupancy improvement to 55-60% in the next year through aggressive sales, marketing, and potential CGHS empanelment.
Expansion plans include new hospitals in Hennur, Coimbatore, Gurugram, and Pune, targeting a total bed capacity of 3,165 by FY28-29.
Maintaining medium-term revenue CAGR guidance of 18%.
Digital initiatives and specialty expansion (e.g., liver transplants) to drive future growth.
The company continues to monitor regulatory changes, including new labour codes, and will adjust accounting as needed.
Latest events from Rainbow Children's Medicare
- Q1 FY25 revenue up 15% YoY, EBITDA up 6.9%, with expansion, capex, and top accreditations.RAINBOW
Q1 24/2518 Jun 2026 - Q2 FY25 saw record revenue, strong margins, expansion, and clinical excellence despite global headwinds.RAINBOW
Q2 24/2518 Jun 2026 - Q1 FY26 saw 6.9% revenue growth, 35.4% higher net profit, and ongoing network expansion.RAINBOW
Q1 25/2618 Jun 2026 - Q3 FY25 revenue up 18.5% YoY, EBITDA up 14%, and new ESOP scheme approved.RAINBOW
Q3 24/2518 Jun 2026 - FY25 revenue up 17% YoY, profit and margins rose, with expansion and dividend proposed.RAINBOW
Q4 24/2518 Jun 2026 - Q4 FY26 saw record growth, major expansion, and a proposed ₹3.50/share dividend.RAINBOW
Q4 25/2625 May 2026 - Q2 FY26 revenue up 6.5% YoY, net profit down 4%, with major acquisitions and expansion plans.RAINBOW
Q2 25/2614 Nov 2025